TORTINI

For your delectation and delight, desultory dicta on the law of delicts.

Ecological Fallacy Goes to Court

June 30th, 2012

In previous posts, I have bemoaned the judiciary’s tin ear for important qualitative differences between and among different research study designs.  The Reference Manual for Scientific Evidence (3d ed. 2011)(RMSE3d) offers inconsistent advice, ranging from Margaret Berger’s counsel to abandon any hierarchy of evidence, to other chapters’ emphasizing the importance of a hierarchy.

The Cook case is one of the more aberrant decisions, which elevated an ecological study, without a statistically significant result, into an acceptable basis for a causal conclusion under Rule 702.  Senior Judge Kane’s decision in the litigation over radioactive contamination from the Colorado Rocky Flats nuclear weapons plant is illustrative of a judicial refusal to engage with the substantive differences among studies, and to ignore the inability of some study designs to support causality.  See Cook v. Rockwell Internat’l Corp., 580 F. Supp. 2d 1071, 1097-98 (D. Colo. 2006) (“Defendants assert that ecological studies are inherently unreliable and therefore inadmissible under Rule 702.  Ecological studies, however, are one of several methods of epidemiological study that are well-recognized and accepted in the scientific community.”), rev’d and remanded on other grounds, 618 F.3d 1127 (10th Cir. 2010), cert. denied, ___ U.S. ___ (May 24, 2012).  Senior Judge Kane’s point about the recognition and acceptance of ecological studies has nothing to do with their ability to support conclusions of causality.  This basic non sequitur led the trial judge into ruling that the challenge “goes to the weight, not the admissibility” of the challenged opinion testimony.  This is a bit like using an election day exit poll, with 5% returns, for “reliable” evidence to support a prediction of the winner.  The poll may have been conducted most expertly, but it lacks the ability to predict the winner.

The issue is not whether ecological studies are “scientific”; they are part of the epidemiologists’ toolkit.  The issue is whether they warrant inferences of causation.  Some so-called scientific studies are merely hypothesis generating, preliminary, tentative, or data-dredging exercises.  Judge Kane opined that ecological studies are merely “less probative” than other studies, and the relative weights of studies do not render them inadmissible.  Id.  This is a misunderstanding or an abdication of gatekeeping responsibility.  First, studies themselves are not admissible; it is the expert witness, whose testimony is challenged.  Second, Rule 702 requires that the proffered opinion be “scientific knowledge,” and ecological studies simply lack the necessary epistemic warrant.

The legal sources cited by Senior Judge Kane provide only equivocal and minimal support at best for his decision.  The court pointed to RSME2d at 344-45, for the proposition that ecological studies are useful for establishing associations, but are weak evidence for causality. The other legal citations give seem equally unhelpful.  In re Hanford Nuclear Reservation Litig., No. CY–91– 3015–AAM, 1998 WL 775340 at *106 (E.D.Wash. Aug.21, 1998) (citing RMSE2d and the National Academy of Science Committee on Radiation Dose Reconstruction for Epidemiological Uses, which states that “ecological studies are usually regarded as hypothesis generating at best, and their results must be regarded as questionable until confirmed with cohort or case‑control studies.” National Research Council, Radiation Dose Reconstruction for Epidemiologic Uses at 70 (1995)), rev’d on other grounds, 292 F.3d 1124 (9th Cir. 2002).  Ruff v. Ensign– Bickford Indus., Inc., 168 F.Supp. 2d 1271, 1282 (D. Utah 2001) (reviewing evidence that consisted of a case-control study in addition to an ecological study; “It is well established in the scientific community that ecological studies are correlational studies and generally provide relatively weak evidence for establishing a conclusive cause and effect relationship.’’); see also id. at 1274 n.3 (“Ecological studies tend to be less reliable than case–control studies and are given little evidentiary weight with respect to establishing causation.”)

 

ERROR COMPOUNDED

The new edition of RMSE cites the Cook case at several places.  In an introductory chapter, the late Professor Margaret Berger cites the case incorrectly for having excluded expert witness testimony.  See Margaret A. Berger, “The Admissibility of Expert Testimony 11, 24 n.62 in RMSE3d (“See Cook v. Rockwell Int’l Corp., 580 F. Supp. 2d 1071 (D. Colo. 2006) (discussing why the court excluded expert’s testimony, even though his epidemiological study did not produce statistically significant results).”)  The chapter on epidemiology cites Cook correctly for having refused to exclude the plaintiffs’ expert witness, Dr. Richard Clapp, who relied upon an ecological study of two cancer outcomes in the area adjacent to the Rocky Flats Nuclear Weapons Plant.  See Michael D. Green, D. Michal Freedman, and Leon Gordis, “Reference Guide on Epidemiology,” 549, 561 n. 34, in Reference Manual for Scientific Evidence (3d ed. 2011).  The authors, however, abstain from any judgmental comments about the Cook case, which is curious given their careful treatment of ecological studies and their limitations:

“4. Ecological studies

Up to now, we have discussed studies in which data on both exposure and health outcome are obtained for each individual included in the study.33 In contrast, studies that collect data only about the group as a whole are called ecological studies.34 In ecological studies, information about individuals is generally not gathered; instead, overall rates of disease or death for different groups are obtained and compared. The objective is to identify some difference between the two groups, such as diet, genetic makeup, or alcohol consumption, that might explain differences in the risk of disease observed in the two groups.35 Such studies may be useful for identifying associations, but they rarely provide definitive causal answers.36

Id. at 561.  The epidemiology chapter proceeds to note that the lack of information about individual exposure and disease outcome in an ecological study “detracts from the usefulness of the study,” and renders it prone to erroneous inferences about the association between exposure and outcome, “a problem known as an ecological fallacy.”  Id. at 562.  The chapter authors define the ecological fallacy:

“Also, aggregation bias, ecological bias. An error that occurs from inferring that a relationship that exists for groups is also true for individuals.  For example, if a country with a higher proportion of fishermen also has a higher rate of suicides, then inferring that fishermen must be more likely to commit suicide is an ecological fallacy.”

Id. at 623.  Although the ecological study design is weak and generally unsuitable to support causal inferences, the authors note that such studies can be useful in generating hypotheses for future research using studies that gather data about individuals. Id. at 562.  See also David Kaye & David Freedman, “Reference Guide on Statistics,” 211, 266 n.130 (citing the epidemiology chapter “for suggesting that ecological studies of exposure and disease are ‘far from conclusive’ because of the lack of data on confounding variables (a much more general problem) as well as the possible aggregation bias”); Leon Gordis, Epidemiology 205-06 (3d ed. 2004)(ecologic studies can be of value to suggest future research, but “[i]n and of themselves, however, they do not demonstrate conclusively that a causal association exists”).

The views expressed in the Reference Manual for Scientific Evidence, about ecological studies, are hardly unique.  The following quotes show how ecological studies are typically evaluated in epidemiology texts:

Ecological fallacy

An ecological fallacy or bias results if inappropriate conclusions are drawn on the basis of ecological data. The bias occurs because the association observed between variables at the group level does not necessarily represent the association that exists at the individual level (see Chapter 2).

***

Such ecological inferences, however limited, can provide a fruitful start for more detailed epidemiological work.”

R. Bonita, R. Beaglehole, and T. Kjellström, Basic Epidemiology 43 2d ed. (WHO 2006).

“A first observation of a presumed relationship between exposure and disease is often done at the group level by correlating one group characteristic with an outcome, i.e. in an attempt to relate differences in morbidity or mortality of population groups to differences in their local environment, living habits or other factors. Such correlational studies that are usually based on existing data are prone to the so-called ‘ecological fallacy’ since the compared populations may also differ in many other uncontrolled factors that are related to the disease. Nevertheless, ecological studies can provide clues to etiological hypotheses and may serve as a gateway towards more detailed investigations.”

Wolfgang Ahrens & Iris Pigeot, eds., Handbook of Epidemiology 17-18 (2005).

The Cook case is a wonderful illustration of the judicial mindset that avoids and evades gatekeeping by resorting to the conclusory reasoning that a challenge “goes to the weight, not the admissibility” of an expert witness’s opinion.

Let’s Require Health Claims to Be Evidence Based

June 28th, 2012

Litigation arising from the FDA’s refusal to approval “health claims” for foods and dietary supplements is a fertile area for disputes over the interpretation of statistical evidence.  A ‘‘health claim’’ is ‘‘any claim made on the label or in labeling of a food, including a dietary supplement, that expressly or by implication … characterizes the relationship of any substance to a disease or health-related condition.’’ 21 C.F.R. § 101.14(a)(1); see also 21 U.S.C. § 343(r)(1)(A)-(B).

Unlike the federal courts exercising their gatekeeping responsibility, the FDA has committed to pre-specified principles of interpretation and evaluation. By regulation, the FDA gives notice of standards for evaluating complex evidentiary displays for the ‘‘significant scientific agreement’’ required for approving a food or dietary supplement health claim.  21 C.F.R. § 101.14.  See FDA – Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims – Final (2009).

If the FDA’s refusal to approve a health claim requires pre-specified criteria of evaluation, then we should be asking ourselves why have the federal courts failed to develop a set of criteria for evaluating health effects claims as part of its Rule 702 (“Daubert“) gatekeeping responsibilities.  Why, after close to 20 years after the Supreme Court decided Daubert, can lawyers make “health claims” without having to satisfy evidence-based criteria?

Although the FDA’s guidance is not always as precise as might be hoped, it is far better than the suggestion of the new Reference Manual for Scientific Evidence (3d ed. 2011) that there is no hierarchy of evidence.   See RMSE 3d at 564 & n.48 (citing and quoting idiosyncratic symposium paper that “[t]here should be no hierarchy [among different types of scientific methods to determine cancer causation]; “Late Professor Berger’s Introduction to the Reference Manual on Scientific Evidence” (Oct. 23, 2011).

The FDA’s attempt to articulate an evidence-based hierarchy is noteworthy because the agency must evaluate a wide range of evidence, from in vitro, to animal studies, to observational studies of varying kinds, to clinical trials, to meta-analyses and reviews.  The FDA’s criteria are a good start, and I imagine that they will develop and improve over time.  Although imperfect, the criteria are light years ahead of the situation in federal and state court gatekeeping.  Unlike gatekeeping in civil actions, the FDA criteria are pre-stated and not devised post hoc.  The FDA’s attempt to implement evidence-based principles in the evaluation of health claims made is a model that would much improve the Reference Manual for Scientific EvidenceSee Christopher Guzelian & Philip Guzelian, “Prevention of false scientific speech: a new role for an evidence-based approach,” 27 Human & Experimental Toxicol. 733 (2008).

The FDA’s evidence-based criteria need work in some areas.  For instance, the FDA’s Guidance on meta-analysis is not particularly specific or helpful:

Research Synthesis Studies

Reports that discuss a number of different studies, such as review articles, do not provide sufficient information on the individual studies reviewed for FDA to determine critical elements such as the study population characteristics and the composition of the products used. Similarly, the lack of detailed information on studies summarized in review articles prevents FDA from determining whether the studies are flawed in critical elements such as design, conduct of studies, and data analysis. FDA must be able to review the critical elements of a study to determine whether any scientific conclusions can be drawn from it. Therefore, FDA intends to use review articles and similar publications to identify reports of additional studies that may be useful to the health claim review and as background about the substance/disease relationship. If additional studies are identified, the agency intends to evaluate them individually. Most meta-analyses, because they lack detailed information on the studies summarized, will only be used to identify reports of additional studies that may be useful to the health claim review and as background about the substance-disease relationship.  FDA, however, intends to consider as part of its health claim review process a meta-analysis that reviews all the publicly available studies on the substance/disease relationship. The reviewed studies should be consistent with the critical elements, quality and other factors set out in this guidance and the statistical analyses adequately conducted.”

FDA – Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims – Final at 10 (2009).

The dismissal of review articles as a secondary source is welcome, but meta-analyses are quantitative reviews that can add additional insights and evidence, if methodologically appropriate, by providing a summary estimate of association, sensitivity analyses, meta-regression, etc.  The FDA’s guidance was applied in connection with the agency’s refusal to approve a health claim for vitamin C and lung cancer.  Proponents claimed that a particular meta-analysis supported their health claim, but the FDA disagreed.  The proponents sought injunctive relief in federal district court, which upheld the FDA’s decision on vitamin C and lung cancer.  Alliance for Natural Health US v. Sebelius, 786 F.Supp. 2d 1, 21 (D.D.C. 2011).  The district court found that the FDA’s refusal to approve the health claim was neither arbitrary nor capricious with respect to its evaluation of the cited meta-analysis:

‘‘The FDA discounted the Cho study because it was a ‘meta-analysis’ of studies reflected in a review article. FDA Decision at 2523. As explained in the 2009 Guidance Document, ‘research synthesis studies’, and ‘review articles’, including ‘most meta-analyses’, ‘do not provide sufficient information on the individual studies reviewed’ to determine critical elements of the studies and whether those elements were flawed. 2009 Guidance Document at A.R. 2432. The Guidance Document makes an exception for meta-analyses ‘that review[ ] all the publicly available studies on the substance/disease relationship’. Id. Based on the Court’s review of the Cho article, the FDA’s decision to exclude this article as a meta-analysis was not arbitrary and capricious.’’

Id. at 19.

The FDA’s Guidance was adequate for its task in the vitamin C/lung cancer health claim, but notably absent from the Guidance are any criteria to evaluate competing meta-analyses that do include “all the publicly available studies on the substance/disease relationship.”  The model assumptions of meta-analyses, fixed effect versus random effects, lack of heterogeneity, as well as other considerations will need to be spelled out in advance.  Still not a bad start.  Implementing evidence-based criteria in Rule 702 gatekeeping has the potential to tame the gatekeeper’s discretion.

Gatekeeping the Lumpers and Splitters – Composite End Points

June 26th, 2012

The battle between lumpers and splitters is fought in many disciplines, and so it is not surprise that it finds its way into litigation.

The battle is often entrenched in the discipline of epidemiology, where practitioners tussle over the definition of the end point of a study or clinical trial. Lumping has the advantage of increasing study size, with attendant increases in statistical power.  The down side of lumping is that the “lumped” or composite outcome may no longer be meaningful with respect to the more precise outcome of interest.  In other words, the lumping threatens the external validity of the study.  Splitting preserves external validity with respect to outcome of interest, but decreases study size, with a greater risk of Type II errror.

The issue arises in birth defect litigation, such as the claims made against the manufacturer of Bendectin, where the claimants’ expert witnesses frequently tried to increase power by lumping different birth defects together, despite the lack of embryological plausibility.  The issue has come up in cardiovascular end point trials and meta-analyses, involving thrombo-embolic outcomes, such as stroke and heart attack.  The Celebrex litigation, for instance, involved contested issues of what cardiovascular end points to combine to capture the postulated thrombotic causal mechanism.  In re Pfizer Inc. Securities Litig., 2010 WL 1047618 (S.D.N.Y. 2010).

Despite the recurrence of lumping/splitting issues in litigation of epidemiologic evidence, the Reference Manual for Scientific Evidence (3d ed. 2011)  does not treat the subject at all.  Federal and state judges are often at sea (without sextant or compass) in disputes over lumping and splitting, where the methodology selected can often determine the result.  The following is a collection of some observations, comments, and guidances from the biomedical literature on the use of composite end points. 

 

Composite Endpoints

A.  Definition

Composite end points are typically defined, perhaps circularly, as a single group of health outcomes, which group is made up of constituent or single end points.  Meinert defined a composite outcome as “an event that is considered to have occurred if any of several different events or outcomes is observed.”  C. Meinert, Clinical Trials Dictionary (Johns Hopkins Center for Clinical Trials 1996). Similarly, Montori defined composite end points as “outcomes that capture the number of patients experiencing one or more of several adverse events.”  Montori, et al., “Validity of composite end points in clinical trials.”  300 Brit. Med. J.  594, 596 (2005).  Composite end points are also sometimes referred to as combined or aggregate end points.

Many composite end points are clearly defined for a clinical trial, and the component end points are specified.  In some instances, the composite nature of an outcome may be subtle or be glossed over by the study’s authors.  In the realm of cardiovascular studies, for example, investigators may look at stroke as a single endpoint, without acknowledging that there are important clinical and pathophysiological differences between ischemic strokes and hemorrhagic strokes (intracerebral or subarachnoid).  The Fletchers give the example:

“In a study of cardiovascular disease, for example, the primary outcomes might be the occurrence of either fatal coronary heart disease or non-fatal myocardial infarction.  Composite outcomes are often used when the individual elements share a common cause and treatment.  Because they comprise more outcome events than the component outcomes alone, they are more likely to show a statistical effect.”

R. Fletcher & S. Fletcher, Clinical Epidemiology: The Essentials 109 (4th ed. 2005).

B.  Utility of Composite End Points

1.  Power

Use of composite end points frequently occurs in the context of studying heart attacks as the outcome of interest.  Improvements in medical care have led to decreased frequency in rates of myocardial infarction (MI) and repeat MIs.  In clinical trials, because of the close medical attention received by participants, event rates are even lower than what might be expected from the relevant general patient population.  These low event rates have caused power issues for clinical trialists, who have responded by turning to composite end points to capture more events.  Composite end points permit smaller sample sizes and shorter follow-up times.  Increasing study power, while reducing sample size or observation time, is perhaps the most frequently cited rationale for using composite end points.

Typical statements from the medical literature:

“Clinical trials, particularly in cardiology, often use composite end points to reduce sample size requirements and to capture the overall impact of therapeutic interventions.”

(Ferreira-Gonzalez 2007, p. 1b, Introduction)

“The widespread use of composite end points reflects their elegant simplicity as a solution to the problem of declining event rates.”

(Montori 2005, at 596, Conclusions)

“The primary rationale for considering a composite primary outcome instead of a single event outcome is sample size.”

(Neaton 2005, at 598b)

“Clinical trialists use composite end points, outcomes that capture the number of patients who have one or more of several events, to increase event rates and statistical power.”

(Ferreira-Gonzalez 2007, p. 6a, Box)

“Although dealing with multiple testing is an important factor in the design and analysis of clinical trials, this may not be the only motivation behind the popularity of composite outcome measures.  Instead, issues of statistical efficiency appear to be prominent, with composite outcomes in time-to-event trials leading to higher event rates and thus enabling smaller sample sizes or shorter follow-up (or both).”

(Freemantle 2003, at 2555 b-c)

“Investigators often use composite end points to enhance the statistical efficiency of clinical trials.”

(Montori 2004, at 1094b)

2.  Competing Risks

Another reason that is offered in support of using composite end points is composites provide a strategy to avoid the problem of competing risks.  (Neaton 2005, at 569a)  Death (any cause) is sometimes added to a distinct clinical morbidity because patients who are taken out of the trial by death are “unavailable” to experience the morbidity outcome.

3.  Multiple Testing

By aggregating several individual end points into a single pre-specified outcome, trialists can avoid corrections for multiple testing.  Trials that seek data on multiple outcomes, or on multiple subgroups, inevitably raise concerns about the appropriate choice of the measure for the statistical test (alpha) to determine whether to reject the null hypothesis.  According to some authors, “[c]omposite endpoints alleviate multiplicity concerns.”  Schulz & Grimes, “Multiplicity in randomized trials I:  endpoints and treatments,” 365 Lancet 1591, 1593a (2005).  Schultz and Grimes, who written extensively about methodological issues, comment further:

“If designated a priori as the primary outcome, the composite obviates the multiple comparisons associated with testing of the separate components.  Moreover, composite outcomes usually lead to high event rates thereby increasing power or reducing sample size requirements.  Not surprisingly, investigators frequently use composite endpoints.”

Id.  Freemantle and Calvert acknowledge that the need to avoid false positive results from multiple testing is an important rationale for composite end points:

“Because the likelihood of observing a statistically significant result by chance alone increases with the number of tests, it is important to restrict the number of tests undertaken and limit the type 1 error to preserve the overall error rate for the trial.”

Freemantle & Calvert, “Composite and surrogate outcomes in randomized controlled trials.” 334 Brit. Med. J . 756, 756a – b (2007).  Freemantle previously had articulated a similar rationale:

“[T]he correct (a priori) identification of a composite end point can increase the statistical precision and thus the efficiency of a trial.”

(Freemantle 2003, at 2558a)

4.  Indecision about an Appropriate Single Outcome

The International Conference on Harmonization suggests that the inability to select a single outcome variable may lead to the adoption of a composite outcome:

“If a single primary variable cannot be selected …, another useful strategy is to integrate or combine the multiple measurements into a single or composite variable.”

International Conference on Harmonisation of Technical Requrements for Registration of Pharmaceuticals for Human Use; “ICH harmonized tripartite guideline:  statistical principles for clinical trials,” 18 Stat. Med. 1905 (1999).

Freemantle gives this rationale some measure of approval:

“Composite outcomes can help in avoiding arbitrary decisions between different candidate outcomes when prespecifying the primary outcome … .”

(Freemantle & Calvert 2007, at 757a)

“[A] composite outcome may help investigators who are having difficulty in deciding which outcome to elect as the primary outcome measure in a trial and deal with the issue of multiplicity in an efficient manner, avoiding the need for arbitrary choices.”

(Freemantle 2003, at 2558a-b)

The “indecision” rationale has also been criticized:

“Inability to reach consensus on a single outcome is generally not a good reason to use a composite end point.”

(Neaton 2005, at 569b)

 

C.  Validity of Composite End Points

The validity of composite end points depends upon assumptions, which will have to be made at the time of the study design and protocol creation.  After the data are collected and analyzed, the assumptions may or may not be supported.

“The validity of composite end points depends on

  • similarity in patient importance,
  • [similarity in] treatment effect, and
  • number of events across the components.”

(Montori 2005, at 596, Summary Point No. 2)

“Use of composite end points is usually justified by the assumption that the effect on each of the components will be similar and that patients will attach similar importance to each component.”

(Montori 2005, at 594a, paragraph 2)

 

D.  Role of Mechanism in Justifying Composite End Points

A composite end point will obviously make sense when the individual end points are biologically related, and the investigators reasonably expect that the individual end points would be affected in the same direction, and in the same approximate amount.

“Confidence in a composite end point rests partly on a belief that similar reductions in relative risk apply to all the components.  Investigators should therefore construct composite endpoints in which the biology would lead us to expect similar effects across components.”

(Montori 2005, 595b)

 

E.  Methodological Issues

The acceptability of composite end points is often a delicate balance between the statistical power and efficiency gained and the reliability concerns raised by using the composite.  As with any statistical or interpretative tool, the key questions revolve how is the tool used, and for what purpose.  The reliability issues raised by the use of composites are likely to be highly contextual.

For instance, there is an important asymmetry between justifying the use of a composite for measuring efficacy and the use of the same composite for safety outcomes.  A biological improvement in type 2 diabetes might be expected to lead to a reduction in all the macrovascular complications of that disease, but a medication for type 2 diabetes might have a very specific toxicity or drug interaction, which affects only constituent end point among all macrovascular complications, such as myocardial infarction.  The asymmetry between efficacy and safety outcomes is specifically addressed in a recent publication:

“Varying definitions of composite end points, such as MACE, can lead to substantially different results and conclusions.  There, the term MACE, in particular, should not be used, and when composite study end points are desired, researchers should focus separately on safety and effectiveness outcomes, and construct separate composite end points to match these different clinical goals.”

(Kip 2008, 701, Abstract – Conclusions)(emphasis in original)

There are many clear statements that caution the consumers of medical studies against being misled by misleading claims that may be based upon composite end points, in the medical literature.  Severally years ago, the British Medical Journal published a paper by Montori, et al., “Users’ guide to detecting misleading claims in clinical research reports,” 329 Brit. Med. J. 1093 (2004).  The authors distill their advice down to six suggestions, one of which deals explicitly with composite end points:

“Guide to avoid being misled by biased presentation and interpretation of data

1.  Read only the Methods and Results sections; bypass the Discuss section

2.  Read the abstract reported in evidence based secondary publications

3.  Beware faulty comparators

4.  Beware composite endpoints

5.  Beware small treatment effects

6.  Beware subgroup analyses”

 

 

 

 

 

 

 

 

 

 

 

Id. at 1093a (emphasis added).  The authors elaborate on the problems that arise from the use of composite end points:

“Problems in the interpretation of these trials arise when composite end points include component outcomes to which patients attribute very different importance… .”

(Montori 2004, at 1094b.)

“Problems may also arise when the most important end point occurs infrequently or when the apparent effect on component end points differs.”

(Montori 2004, at 1095a.)

“When the more important outcomes occur infrequently, clinicians should focus on individual outcomes rather than on composite end points.  Under these circumstances, inferences about the end points (which because they occur infrequently will have very wide confidence intervals) will be weak.”

(Montori 2004, at 1095a.)

“When large variations exist between components the composite end point should be abandoned.”

(Montori 2005, at 596, Summary Point No. 3)

“Occasionally, composite end points prove useful and informative for clinical decision making.  Often, they do not.”

(Montori 2005, at 596, Conclusions)

“Composite endpoints frequently lack clinical relevancy.  Thus, composite endpoints address multiplicity and generally yield statistical efficiency at the risk of creating interpretational difficulties.”

(Schulz & Grimes 2005, at 1593a-b)

“The disadvantages of composite outcomes may arise when the constituents do not move in line with each other.”

(Freemantle 2003, at 2558a)

“Composite end points, as currently used in cardiovascular trials, may often be misleading.”

(Ferreira-Gonzalez 2007, p. 6a, Box)

“Trialists should report complete data on individual component end points to facilitate appropriate interpretation; clinicians should view with caution the results of cardiovascular trials that use composite end points to report their results.”

(Ferreira-Gonzalez 2007, p. 7a)

 

F.  Methodological Issues Concerning Causal Inferences from Composite End Points to Individual End Points

Several authors have criticized pharmaceutical companies for using composite end points to “game” their trials.  Composites allow smaller sample size, but they lend themselves to broader claims for outcomes included within the composite.  The same criticism appears to be valid when applied to attempts to infer that there is risk of an individual endpoint based upon a showing of harm in the composite endpoint.

“If a trial report specifies a composite endpoint, the components of the composite should be in the well-known pathophysiology of the disease.  The researchers should interpret the composite endpoint in aggregate rather than as showing efficacy of the individual components.  However, the components should be specified as secondary outcomes and reported beside the results of the primary analysis.”

(Schulz & Grimes 2005, at 1595a)(emphasis added)

“[A] positive result for a composite outcome applies only to the cluster of events included in the composite and not to the individual components.”

(Freemantle & Calvert 2007, at 757a) [Freemantle and Calvert urge “health warnings” that a composite end point benefit cannot be interpreted to mean an actual benefit in every constituent end point.]

“To avoid the burying of important components of composite primary outcomes for which on their own no effect is concerned, . . . the components of a composite outcome should always be declared as secondary outcomes, and the results described alongside the result for the composite outcome.”

(Freemantle 2003, at 2559a, Point No. 3; 2559b-c, Box)

“Authors and journal editors should ensure that the reporting of composite outcomes is clear and avoids the suggestion that individual components of the composite have been demonstrated to be effective.”

(Freemantle 2003, at 2559b-c, Box Point No. 4)

 

G.  Regulatory Experience

“Regulatory behavior may have led to the addition of ‘death’ to many composite primary end points used in trials, and it is our experience that the Food and Drug Administration has actively promoted the use of such composite outcome measures in the heart failure trials.”

(Freemantle & Calvert 2007, at 757a)

The FDA addressed composite end points in the context of its recommendations for looking at cardiovascular outcomes in Phase III and Phase IV clinical trials for anti-diabetic therapies.

“In cardiovascular trials, as in all trials, the primary endpoint should be predefined, justified, and accurately captured and analyzed. Powering the study on an individual type of event (e.g., myocardial infarction) is usually not feasible because of low incidence rates. Therefore, many cardiovascular trials use the MACE (Major Adverse Cardiovascular Event) composite endpoint, which contains all-cause mortality (or cardiovascular death), non-fatal myocardial infarction, and stroke. Some cardiovascular trials include other macrovascular events, such as coronary revascularization and lower-extremity amputation. Use of all-cause mortality as part of the MACE endpoint in a trial with excellent follow-up has the advantage of certainty as to whether the event occurred. However, the cause of death should still be determined in a well-designed trial to ensure that there are no imbalances in particular fatal events (e.g., neoplasms or strokes). Use of cardiovascular death as part of the MACE endpoint may be more relevant but, like myocardial infarction and stroke, requires adjudication by an independent and blinded committee with pre-specified case definitions and methodology for ascertaining events (e.g., access to medical records and laboratory data).  If the study is powered on a composite endpoint, there will likely be too few events for the individual components (e.g., acute myocardial infarction) of the composite to provide conclusive evidence of a difference between treatment groups with regard to these individual endpoints. In addition, a difference between treatment groups in the composite endpoint may primarily be driven by one or more of the individual components that comprise the endpoint. As a result, secondary efficacy measures often include analyses of the individual components as initial and total events to determine their contribution to the overall primary efficacy results.”

(FDA Background Introductory Memorandum, for Endocrinologic and Metabolic Drugs Advisory Committee meeting, July 1-2, 2008, at p. 17 – 18.)

 

H.  Specific Composite End Points

1.  Myocardial ischemia 

In the Avandia litigation, some investigators chose to look at a composite of “myocardia ischemia.”  Plaintiffs’ counsel, and even some publications, appear to equate a finding of this composite end point with one of myocardial infarction.  For instance, Curt Furberg equated MI with myocardial ischemia in a JAMA publication of his meta-analysis of rosiglitazone trials.  See, e.g., Singh, et al., “Long-term risk of cardiovascular events with rosiglitazone:  a meta-analysis,” 298 JAMA 1189, 1193 (2007)(“Two previous meta-analyses showed that the risk of MI was significantly increased by rosiglitazone. An unpublished meta-analysis (ZM 2005/00181/01) conducted in 2005 involving 14,237 participants from 42 double-blind RCTs determined the incidence of MI in the rosiglitazone group to be 1.99% vs. 1.51% in controls (hazard ratio, 1.31; 95% CI, 1.01-1.70).”)(emphasis added; internal references omitted).  From his endnotes, it is clear that Furberg is referencing GlaxoSmithKline’s own meta-analysis, which used myocardial ischemia, not MI, as an end point.  See Alexander Cobitz, et al., “A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone,” 17 Pharmacoepi. and Drug Safety 769 (2008) (reporting GSK’s meta-analysis of 42 clinical trials for a broad definition of myocardial ischemia).  Furberg’s confusion seems the sort of carelessness that trial judges should be alert to guard against.

Myocardial ischemia may be variously defined, but at least it may include MI and angina.  Sometimes revascularization is added.  Subjective symptoms as vague as “dyspnea,” or as specific as sub-sternal pain, may be part of the definition.  A definition of myocardial ischemia used in an exploratory, hypothesis-generating analysis, for purposes of “pharmacovigilance,” may have different validity and operational characteristics from a definition used in a study that is trying to determine whether a medication, does in fact, cause any one of the constituent end points within the composite.

2.  MACE

Recently, the use of the MACE composite end point has been subjected to greater scrutiny and criticism.  Kip summarizes his group’s recent analysis:

“In light of the approximate prior 15 years of the term MACE and its wide heterogeneity in definition and research applications, it is unlikely that a consensus definition will either be universally desired or practical for future research.  Therefore, we recommend against the routine use of MACE as a composite end point at large.  However, if a broad heterogeneous composite end point such as MACE is ultimately desired, minimally, it must be clearly defined, and the individual as well as composite end points need to be analyzed, presented, and discussed.”

(Kip 2008, at 706b)

Kip notes that this his group’s recommendations are consistent with those of the Academic Research Consortium, which has tried to establish consensus composite end point definitions for stent trials.  See Cutlip, et al., “Clinical end points in coronary stent trials:  a case for standardized definitions,” 115 Circulation 2344 (2007).

3.  Cardiovascular or cardiac death

The use of a composite end point of cardiac death has elicited some strong criticism in the published literature, most notably from Dr. Nissen’s former colleague, Dr. Eric Topol.  See generally, Lauer & Topol, “Clinical trials – Multiple treatments, multiple end points, and multiple lessons,” 289 JAMA 2575 (2003).

“Among fatal end points, only all-cause mortality can be considered objective, unbiased, and clinically relevant.  As previously reviewed in depth, the use of end points such as ‘cardiac death’, ‘vascular death’, and ‘arrhythmic death’ are inherently subject to error due to biased assessment and to the biological complexities of disease, especially among elderly individuals.”

(Lauer & Topol 2003, at 2575b)

“When mortality is considered, only all-cause mortality is a valid end point, while end points such as ‘cardiac death’ and ‘arrhythmic death’ should be actively discouraged.”

(Lauer & Topol 2003, at 2577a)

4.  All-cause death

Although most authors accept “any death” as a potential corrective to competing risks, and the ultimate, objective outcome, Lauer and Topol do not completely spare the inclusion of all-cause death in outcome composites, from criticism:

“A composite end point that includes death as well as nonfatal events is subject to biases related to competing risks.  Obviously, patients who die cannot later experience nonfatal myocardial infarction or be hospitalized.  A treatment that leads to an increased risk of death may therefore appear to reduce the risk of nonfatal events.  Although formal methods have been developed to analyze competing risks in an unbiased manner, the optimal approach to this problem is unclear.”

(Lauer & Topol 2003, at 2576a)

 

J.   Bibliography

Cutlip, et al., “Clinical end points in coronary stent trials:  a case for standardized definitions,” 115 Circulation 2344 (2007)

FDA Background Introductory Memorandum, for Endocrinologic and Metabolic Drugs Advisory Committee meeting (July 1-2, 2008)

Ferreira-Gonzalez, et al., “Problems with the use of composite end point in cardiovascular trials: systematic review of randomized controlled trials.”  334 Brit. Med. J.  (published online 2 April 2007).

R. Fletcher & S. Fletcher, Clinical Epidemiology:  The Essentials (4th ed. 2005).

Freemantle, et al., “Composite outcomes in randomized trials: Greater precision but with greater uncertainty.”  289 J. Am. Med. Ass’n  2554 (2003)

Freemantle & Calvert, “Composite and surrogate outcomes in randomized controlled trials.” 334 Brit. Med. J.  756 (2007)

International Conference on Harmonisation of Technical Requrements for Registration of Pharmaceuticals for Human Use.  ICH harmonized tripartite guideline:  statistical principles for clinical trials, 18 Stat. Med. 1905 (1999)

Kip, et al., “The problem with composite end points in cardiovascular studies,” 51 J. Am. Coll. Cardiol. 701 (2008)

Lauer & Topol, “Clinical trials – Multiple treatments, multiple end points, and multiple lessons.”  289 J. Am. Med. Ass’n 2575 (2003)

Montori, et al., “Users’ guide to detecting misleading claims in clinical research reports,” 329 Brit. Med. J. 1093 (2004)

Montori, et al., “Validity of composite end points in clinical trials.”  300 Brit. Med. J. 594 (2005).

Neaton, et al., “Key issues in end point selection for heart failure trials:  composite end points,” 11 J. Cardiac Failure 567 (2005)

Schulz & Grimes, “Multiplicity in randomized trials I:  endpoints and treatments,” 365 Lancet 1591 (2005)

Meta-Meta-Analysis – Celebrex Litigation – The Claims – Part 2

June 25th, 2012

IMPUTATION

As I noted in part one, the tables were turned on imputation, with plaintiffs making the same accusation that G.E. made in the gadolinium litigation:  imputation involves adding “phantom events” or “imaginary events to each arm of ‘zero event’ trials.”  See Plaintiffs’ Reply Mem. of Law in Further Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 8, 9 (May 5, 2010), in Securities Litig.

The plaintiffs claimed that Wei “created” an artifact of a risk ratio of 1.0 by using imputation in each of the zero-event trials.  The reality, however, is that each of those trials had zero risk difference, and the rates of event in drug and placebo arms were both low and equal to one another.  The plaintiffs’ claim that Wei “diluted” the risk is little more than saying that he failed to inflate the risk by excluding zero-event trials.  But zero-event trials represent a test in which the risk of events in both arms is equal, and relatively low.

The plaintiffs seemed to make their point half-heartedly.  They admitted that “imputation in and of itself is a commonly used methodology,” id. at 10, but they claimed that “adding zero-event trials to a meta-analysis is debated among scientists.”  Id.  A debate over methodology in the realm of meta-analysis procedures hardly makes any one of the debated procedures “not generally accepted,” especially in the context of meta-analysis of uncommon adverse events arising in clinical trials designed for other outcomes.  After all, investigators do not design trials to assess a suspected causal association between a medication and an adverse outcome as their primary outcome.  The debate over the ethics of such a trial would be much greater than any gentle debate over whether to include zero-event trials by using either the risk difference or imputation procedures.

The gravamen of the plaintiffs’ complaint against Wei seems to be that he included too many zero-event trials, “skewing the numbers greatly, and notably cites to no publications in which the dominant portion of the meta-analysis was comprised of studies with no events.”  Id. The plaintiffs further argue that Wei could have minimized the “distortion” created by imputation by using a fractional event, ” a smaller number like .000000001 to each trial.”  Id. The plaintiffs notably cited no texts or articles for this strategy.  In any event, if the zero-event trials are small, as they typically are, then they will have large study variances.  Because meta-analyses weight each trial by the inverse of the variance, studies with large variances have little weight in the summary estimate of association.  Including small studies with imputation methods will generally not affect the outcome very much, and their contribution may well reflect the reality of lower or non-differential risk from the medication.

Eliminating trials on the grounds that they had zero events has also been criticized for throwing away important data.  Charles H. Hennekens, David L. DeMets, C. Noel Bairey Merz, Steven L. Borzak, Jeffrey S. Borer,  “Doing More Harm Than Good,” 122 Am. J. Med. 315 (2009) (criticizing Nissen’s meta-analysis of rosiglitazone in which he excluded zero event trials for as biased towards overestimating the magnitude of the summary estimate of association). George A. Diamond, L. Bax, S. Kaul, “Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death,” 147 Ann. Intern. Med. 578 (2007) (conducting sensitivity analyses on Nissen’s meta-analysis of rosiglitazone to show that Nissen’s findings lost statistical significance when continuity corrections were made for zero-event trials).

 

RISK DIFFERENCE

The plaintiffs are correct that the risk difference is not the predominant risk measure used in meta-analysis or in clinical trials for that matter.  Researchers prefer risk ratios because they reflect base rates in the ratio.  As one textbook explains:

“the limitation of the [risk difference] statistic is its insensitivity to base rates. For example, a risk that increases from 50% to 52% may be less important than one that increases from 2% to 4%, although in both instances RD = 0.02.”

Julia Littell, Jacqueline Corcoran, and Vijayan Pillai, Systematic Reviews and Meta-Analysis 85 (Oxford 2008).  This feature of the risk difference hardly makes its use unreliable, however.

Pfizer pointed out that at least one other case addressed the circumstances in which the risk difference would be superior to risk ratios in meta-analyses:

“The risk difference method is often used in meta-analyses where many of the individual studies (which are all being pooled together in one, larger analysis) do not contain any individuals who developed the investigated side effect.FN17  whereas such studies would have to be excluded from an odds ratio calculation, they can be included in a risk difference calculation. FN18

FN17. This scenario is more likely to occur when studying a particularly rare event, such as suicide.

FN18. Studies where no individuals experienced the effect must be excluded from an odds ratio calculation because their inclusion would necessitate dividing by zero, which, as perplexed middle school math students come to learn, is impossible. The risk difference’s reliance on subtraction, rather than division, enables studies with zero incidences to remain in a meta-analysis. (Hr’g Tr. 310-11, June 20, 2008 (Gibbons.)).”

In re Neurontin Marketing, Sales Practices, and Products Liab. Litig.,  612 F.Supp. 2d 116, 126 (D. Mass. 2009) (MDL 1629).  See Pfizer’s Defendants’ Mem. of Law in Opp. to Plaintiffs’ Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei (Sept. 8, 2009), in Securities Litig. (citing In re Neurontin).

Pfizer also pointed out that Wei had employed both the risk ratio and the risk difference in conducting his meta-analyses, and that none of his summary estimates of association were statistically significant.  Id. at 19, 24.


EXACT CONFIDENCE INTERVALS

The plaintiffs argued that the use of “exact confidence” intervals was not scientifically reliable and could not have been used by Pfizer at the time period covered by the securities class’s allegations.  See Plaintiffs’ Reply Mem. of Law in Further Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 15 (May 5, 2010).  Exact intervals, however, are hardly a novelty, and there is often no single way to calculate a confidence interval.  See E. B. Wilson,  “Probable inference, the law of succession, and statistical inference,” 22 J. Am. Stat. Ass’n 209 (1927); C. Clopper, E. S. Pearson, “The use of confidence or fiducial limits illustrated in the case of the binomial,” 26 Biometrika 404 (1934).  Approximation methods are often used, despite their lack of precision, because of their ease in calculation.

Plaintiffs further claimed that the combination of risk difference and exact intervals is novel, not reliable, and not in existence during the class period.  Plaintiffs’ Reply Mem at 15.  The plaintiffs’ argument traded on Wei’s having published on the use of exact intervals in conjunction with the risk difference for heart attacks in clinical trials of Avandia.  See L. Tian, T. Cai, M.A. Pfeffer, N. Piankov, P.Y. Cremieux, and L.J. Wei, “Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction,” 10 Biostatistics 275 (2009).  Their argument ignored that Wei combined two well-understood statistical techniques, in a transparent way, with empirical testing of the validity of his approach.  Contrary to plaintiffs’ innuendo, Wei did not develop his approach as an expert witness for GlaxoSmithKline; a version of the manuscript describing his approach was posted on line well before he was ever contacted by GSK counsel. (L.J. Wei, personal communication)  Plaintiffs also claimed that Wei’s use of exact intervals for risk difference showed no increased risk of heart attack for Avandia, contrary to a well-known meta-analysis by Dr. Steven Nissen.  See Steven E. Nissen, M.D., and Kathy Wolski, M.P.H., “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes,” 356 New Engl. J. Med. 2457, 2457 (2007).  This claim, however, is a crude distortion of Wei’s paper, which showed that there was a positive risk difference for heart attacks in the same dataset used by Nissen, but the confidence intervals included zero (no risk difference), and thus chance could not be excluded as explaining Nissen’s result.

 

DURATION OF TRIALS

Pfizer was ultimately successful in defending the Celebrex litigation on the basis of lack of risk associated with 200 mg/day use.  Pfizer also attempted to argue a duration effect on grounds that in one large trial that saw a statistically significant hazard ratio associated with higher doses, the result occurred for the first time among trial participants on medication, at 33 months into the trial.  Judge Bryer rejected this challenge, without explanation.  In re Bextra & Celebrex Marketing Celebrex Sales Practices & Prod. Liab. Litig., 524 F.Supp. 2d 1166, 1183 (2007).  The reasonable inference, however, is that the meta-analyses showed statistically significant results across trials with less duration of use, for 400 mg and 800 mg/day use.

Clearly duration of use is a potential consideration unless the mechanism of causation is such that a causally related adverse event would occur from the first use or very short-term use of the medication.  See In re Vioxx Prods. Liab. Litig., MDL No. 1657, 414 F. Supp. 2d. 574, 579 (E.D. La. 2006) (“A trial court may consider additional factors in assessing the scientific reliability of expert testimony . . . includ[ing] whether the expert’s opinion is based on incomplete or inaccurate dosage or duration data.”).  In the Celebrex litigation, plaintiffs’ counsel appeared to want to have duration effects both ways; they did not want to disenfrancise plaintiffs whose claims turned on short-term use, but at the same time, they criticized Professor Wei for including short-term trials of Celebrex.

One form that the plaintiffs’ criticism of Wei took was his failure to weight the trials included in his meta-analyses by duration.  In the plaintiffs’ words:

“Wei failed to utilize important information regarding the duration of the clinical trials that he analyzed, information that is critical to interpreting and understanding the Celebrex and Bextra safety information that is contained within those clinical trials.3 Because the types of cardiovascular events that are at issue in this case occur relatively rarely and are more likely to be observed after an extended period of exposure, the scientific community is in agreement that they would not be expected to appear in trials of very short duration.”

Plaintiffs’ Mem. of Law in Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 2 (July 23, 2009), submitted in In re Pfizer, Inc. Securities Litig., Nos. 04 Civ. 9866(LTS)(JLC), 05 md 1688(LTS) (S.D.N.Y.)[hereafter Securities Litig.]  The plaintiffs maintained that Wei’s meta-analyses were “fatally flawed” because he ignored trial duration, such as would be factored in by performing the analyses in terms of patient years.  Id. at 3

Many of the sources cited by plaintiffs do not support their argument. For instance, the plaintiffs cited articles that noted that weighted averages should be used, but virtually all methods, including Wei’s, weight studies by their variance, which takes into account sample size. Id. at 9 n.3, citing Egger, et al. “Meta-analysis: Principles and Procedures,” 315 Brit. Med. J. 1533 (1997) (an arithmetic average from all trials gives misleading results as results from small studies are more subject to the play of chance and should be given less weight. Meta-analyses use weighted results in which larger trials have more influence that smaller ones). See also id. at 22.  True, true, and immaterial.  No one in the Celebrex cases was using an arithmetic average of risk across trials or studies.

Most of the short-term studies were small, and thus contributed little to the overall summary estimate of association.  Some of the plaintiffs’ citations actually supported using “individual patient data” in the form of time-to-event analyses, which was not possible with many of the clinical trials available.  Indeed, the article the plaintiffs cited, by Dahabreh, did not use time-to-event data for rosiglitazone, because such data were not generally available.  Id. at 9 n.3, citing Dahabreh, “Meta-Analysis Of Rare Events: An Update And Sensitivity Analysis Of Cardiovascular Events In Randomized Trials Of Rosiglitazone,” 5 Clinical Trials 116 (2008).

The plaintiffs’ claim was thus a fairly weak challenge to using simple 2 x 2 tables for the included studies in Wei’s meta-analysis. Both sides failed to mention that many published meta-analyses eschew “patient years” in favor of a simple odds ratio for dichotomous count data from each included study.  See, e.g., Steven E. Nissen, M.D., and Kathy Wolski, M.P.H., “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes,” 356 New Engl. J. Med. 2457, 2457 (2007)(using Peto method with count data, for fixed effect model).  Patient years would be a crude tool to modify the fairly common 2 x 2 table.  The analysis for large studies, with a high number of patient years, would still not reveal whether the adverse events occurred early or late in the trials.  Only a time-to-event analysis could provide the missing information about “duration,” and neither side’s expert witnesses appeared to use a time-to-event analysis.

Interestingly, plaintiffs’ expert witness, Prof. Madigan appears to have received the patient-level data from Pfizer’s clinical trials, but still did not conduct a time-to-event analysis.  Plaintiffs’ Mem. of Law in Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 12 (July 23, 2009), submitted in In re Pfizer, Inc. Securities Litig., Nos. 04 Civ. 9866(LTS)(JLC), 05 md 1688(LTS) (S.D.N.Y.)[hereafter Securities Litig] (noting that Madigan had examined all SAS data files produced by Pfizer, and that “[t]hese  files contained voluminous information on each subject in the trials, including information about duration of exposure to the drug ( or placebo), any adverse events experienced and a wide variety of other information.”).  Of course, even with time-to-event data from the Pfizer clinical trials, Madigan had the problem of whether to limit himself to just the Pfizer trials or use all the data, including non-Pfizer trials.  If he opted for completeness, he would have been forced to include trials for which he did not have underlying data.  In all likelihood, Madigan used patient-years in his analyses because he could not conduct a complete analysis with time-to-event data for all trials.

The plaintiffs’ point appears well taken if the court were to assume that there really was a duration issue, but the plaintiffs’ theories were to the contrary, and Pfizer lost its attempt to limit claims to those events that appeared 33 months (or some other fixed time) after first ingestion.  It is certainly correct that patient-year analyses, in the absence of time-to-event analyses, is generally preferred.  Pfizer had used patient-year information to analyze combined trials in its submission to the FDA’s Advisory Committee.  See Pfizer’s Submission of Advisory Committee Briefing Document at 15 (January 12, 2005).  See also  FDA Reviewer Guidance: Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review at 22 (2005); see also id. at 15 (“If there is a substantial difference in exposure across treatment groups, incidence rates should be calculated using person-time exposure in the denominator, rather than number of patients in the denominator.”);  R. H. Friis & T. A. Sellers, Epidemiology for Public Health Practice at 105 (2008) (“To allow for varying periods of observation of the subjects, one uses a modification of the formula for incidence in which the denominator becomes person-time of observation”).

Professor Wei chose not to do a “patient-year” analysis because such a methodological commitment would have required him to drop over a dozen Celebrex clinical trials involving thousands of patients, and dozens of heart attack and stroke events of interest.  Madigan’s approach led him to disregard a large amount of data.  Wei could, of course, stratified the summary estimates for different length clinical trials, and analyzed whether there were differences as a function of trial duration.  Pfizer claimed that Wei conducted a variety of sensitivity analyses, but it is unclear whether he ever used this technique.  Wei should have been allowed in any event to take plaintiffs at their word that thrombotic events from Celebrex occurred shortly after first ingestion.   Pfizer Mem. of Law in Opp. to Plaintiffs’ Motion to Exclude Defendants’ Expert Dr. Lee-Jen Wei at 2 (Sept. 8, 2009), in Secur. Litig.

 

MADIGAN’S META-ANALYSIS

According to Pfizer, Professor Madigan reached different results from Wei’s largely because he had used different event counts and end points.  The defendants’ challenge to Madigan turned largely upon the unreliable way he went about counting events to include in his meta-analyses.

Data concerning unexpected adverse events in clinical trials often is collected as reports of treating physicians, whose descriptions may be incomplete, inaccurate, or inadequate.  When there is a suggestion that a particular adverse event – say heart attack – occurred more frequently in the medication arm as opposed to the placebo or comparator arms, the usual course of action is to have a panel of clinical experts review all the adverse event reports, and supporting medical charts, to provide diagnoses that can be used in a more complete statistical analyses.  Obviously, the reviewers should be blinded to the patients’ assignment to medication or placebo, and the reviewers should be clinical experts in the clinical specialty of the adverse event.  Cardiologists should be making the call for heart attacks.

In addition to event definition and adjudication, clinical trial interpretation sometimes leads to the use of “composite end points,” which consist of related diagnostic categories, aggregated in some way that makes biological sense.  For instance, if the concern is that a medication causes cardiovascular thrombotic events, a suitable cardiovascular composite end point might include heart attack and ischemic stroke.  Inclusion of hemorrhagic stroke, endocarditis, and valvular disease in the composite, however, would be inappropriate, given the concern over thrombosis.

Professor Madigan is a highly qualified statistician, but, as Pfizer argued, he had no clinical expertise to reassign diagnoses or determine appropriate composite end points.  The essence of the defendants’ challenges revolved around claims of flawed outcome and endpoint ascertainment and definitions.  According to Pfizer’s briefing, the event definition process was unblinded, and conducted by inexpert, partisan reviewers.  Madigan apparently relied upon the work of another plaintiffs’ witness, cardiologist Dr. Lawrence Baruch, as well as that of Dr. Curt Furberg.  Furberg was not a cardiologist; indeed he has never been licensed to practice medicine in the United Dates, and he had not treated a patient in over 30 years. Pfizer Mem. of Law in Opp. to Plaintiffs’ Motion to Exclude Defendants’ Expert Dr. Lee-Jen Wei at 29 (Sept. 8, 2009), in Secur. Litig.  Furthermore, Furberg was not familiar with current diagnostic criteria for heart attack.  Plaintiffs’ counsel asked Furberg to rework some but not all of Baruch’s classifications, but only for fatal events.  Baruch could not explain why Furberg made these reclassifications.  Furberg acknowledged that he had never used “one-line descriptions to classify events,” which he did in the Celebrex litigation, when he received the assignment from plaintiffs’ counsel on the eve of the Court’s deadline for disclosures.  Id. According to Pfizer, if the plaintiffs’ witnesses had used appropriate end points and event counts, their meta-analyses would not have differed from Professor Wei’s work.  Id.

Pfizer pointed to Madigan’s testimony to claim that he had admitted that, based upon the impropriety of Furberg’s changing end point definitions, and his own changes, made without the assistance of a clinician, he would not submit the earlier version of his meta-analysis for peer review.  Pfizer’s [Proposed] Findings of Fact and Conclusions of Law with Respect to Motion to Exclude Certain Plaintiffs’ Experts’ Opinions Regarding Celebrex and Bextra, and Plaintiffs’ Motion to Exclude Defendants’ Expert Dr. Lee-Jen Wei, Document 175, submitted in Securities Litig. (Dec. 4, 2009). at 33,  43.  The plaintiffs countered that Furberg’s reclassifications did not change Madigan’s reports, at least for certain years. Plaintiffs’ Reply Mem. of Law in Further Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 18 (May 5, 2010), in Securities Litig.

The trial court denied Pfizer’s challenges to Madigan’s meta-analysis in the securities fraud class action.  The court attributed any weakness in the classification of fatal adverse events by Baruch and Furberg to the limitations of the underlying data created and produced by Pfizer itself.  In re Pfizer Inc. Securities Litig., 2010 WL 1047618, *4 (S.D.N.Y. 2010).

 

Composites

Pfizer also argued that Madigan put together composite outcomes that did not make biological sense in view of the plaintiffs’ causal theories.  For instance, Madigan left out strokes in his composite, although he included both heart attack and stroke in his primary end point for his Vioxx litigation analysis, and he had no reason to distinguish Vioxx and Celebrex in terms of claimed thrombotic effects.  Pfizer’s [Proposed] Findings of Fact and Conclusions of Law with Respect to Motion to Exclude Certain Plaintiffs’ Experts’ Opinions Regarding Celebrex and Bextra, and Plaintiffs’ Motion to Exclude Defendants’ Expert Dr. Lee-Jen Wei, Document 175, submitted in Securities Litig. (Dec. 4, 2009). at 13-14, 18.  According to Pfizer, Madigan’s composite was novel and unvalidated by relevant, clinical opinion.  Id. at 29, 33.

The plaintiffs’ response is obscure.  The plaintiffs seemed to claim that Madigan was justified in excluding strokes because some kinds of stroke, hemorrhagic strokes, are unrelated to thrombosis.  Plaintiffs’ Reply Memorandum of Law in Further Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 14 (May 5, 2010), in Securities Litig. at 14.  This argument is undermined by the facts:  better than 85% of strokes being ischemic in origin, and even some hemorrhagic strokes start as a result of an ischemic event.

In any event, Pfizer’s argument about Madigan’s composite end points did not gain any traction with the trial judge in the securities fraud class action:

“Dr. Madigan’s written submissions and testimony described clearly and justified cogently his statistical methods, selection of endpoints, decisions regarding event classification, sources of data, as well as the conclusions he drew from his analysis. Indeed, Dr. Madigan’s meta-analysis was based largely on data and endpoints developed by Pfizer. All four of the endpoints that Dr. Madigan used in his analysis-Hard CHD, Myocardial Thromboembolic Events, Cardiovascular Thromboembolic Events, and CV Mortality-have been employed by Pfizer in its own research and analysis. The use of Hard CHD in the relevant literature combined with the use of the other three endpoints by Pfizer in its own 2005 meta-analysis will assist the trier of fact in determining Pfizer’s knowledge and understanding of the pre-December 17, 2004, cardiovascular safety profile of Celebrex.”

In re Pfizer Inc. Securities Litig., 2010 WL 1047618, *4 (S.D.N.Y. 2010).

The Role of the Material Safety Data Sheet in Expert Witness Gatekeeping

June 23rd, 2012

Several years ago, I had an unusual workman’s compensation case, pending in Salem County, New Jersey.  The petitioner claimed that after his employment, he had developed a rare disease as a result of his workplace exposures.  The exact disease really does not matter, other than to note that there was some suggestive epidemiologic evidence of an association, and some evidence against the association.  As a result of the scientific ambiguity, the respondent had started to warn, on its material data safety sheets, and on its packaging, of the association.  So when I stepped into the judge’s chambers, the first thing the petitioner’s counsel said was:  “I win; the employer has admitted causation.”  The judge looked skeptical, and when I pointed out that association is not causation, and that warnings are not statements of scientific conclusions, His Honor agreed enthusiastically.  To the petitioner’s counsel’s shock and dismay, the judge directed us to brief the reliability issue.  Things like that do not often happen in New Jersey, and especially not in a worker’s compensation case.  (A statute of limitations issue ultimately turned out to be dispositive, and we never did get a ruling on the scientific claim.)

The use of the material safety data sheet (MSDS), or warnings on product packaging, is a recurring theme in so-called toxic tort litigation.  The MSDS is a compilation of information about a hazardous material or substance.  Under Occupational Safety and Health Administration (OSHA) regulations, the seller is required to compile information about hazards and provide to purchasers. See 29 C.F.R. § 1910.1200(g) (2006).  Much of the required information is regulatory classification, which is often based upon precautionary judgments about hazards and risks, without information specific to actual exposures likely experienced by end users.  The existence of the MSDS often provides claimants a basis to argue that the seller has admitted causation, but in reality, the argument is little more than a substitution of substituting regulatory precautionary judgment for causal assessments.

The Fifth Circuit’s recent, sure-footed decision in Johnson v. Arkema, Inc., below, reminded me how misleading and how persistent are the expert witnesses who argue causal conclusions based upon MSDS.  The Fifth Circuit recognized that an MSDS cannot be more reliable than the evidence upon which it is based.  Courts need to be on guard against the seductive argument that warnings and MSDS should substitute for scientific evidence of causation.  Unfortunately, not all judges are as astute as the judge I drew in my Salem County worker’s compensation case, which means that there is work to be done.

 

FEDERAL CASES REJECTING RELIANCE UPON MSDS

Johnson v. Arkema Inc., Slip op. at 11-12, 2012 WL ___ (5th Cir. June 20, 2012) (per curiam) (affirming exclusion of expert witnesses who relied in part upon MSDS for two chemicals when the MSDS identified only a very general physical reaction of “respiratory tract irritation,” without identifying the underlying scientific support or specifying the relevant duration and exposure needed to induce any particular adverse outcome)

Pritchard v. Dow AgroSciences, LLC, 705 F. Supp. 2d 471 (W.D. Pa. 2010) (excluding expert witness who opined that Dursban caused NHL based in part upon MSDS), aff’d, 430 Fed. Appx. 102 (3d Cir. 2011), cert. denied, 132 S. Ct. 508 (2011)

Seaman v. Seacor Marine LLC, 564 F. Supp. 2d 598, 603 (E.D. La. 2008) (rejecting reliance on MSDS because, inter alia, “the MSDS … does not mention bladder cancer … as a potential effect”), aff’d, 326 F. App’x 721, 726 (5th Cir. 2009)

Turner v. Iowa Fire Equip. Co., 229 F.3d 1202, 1209 (8th Cir. 2000) (affirming exclusion of expert witness who relied upon MSDS among other things)

Mitchell v. Gencorp Inc., 165 F.3d 778, 781 (10th Cir. 1999) (reliance upon MSDS insufficient)

Moore v. Ashland Chem. Inc., 151 F.3d 269, 278 (5th Cir. 1998) (en banc) (holding that the district court did not abuse its discretion in finding an expert witness’s reliance upon an MSDS because the withness “did not know what tests Dow [Corning] had conducted in generating the MSDS”)

Leake v. United States, 2011 U.S. Dist. LEXIS 149634 (E.D. Pa. 2011) (excluding expert witness who concluded that painting exposure caused liver failure based upon MSDS, etc.)

Henricksen v. ConocoPhillips Co., 605 F. Supp. 2d 1142, 1159 (E.D. Wash. 2009)(excluding expert witness who relied upon MSDS, among other items)

Moore v. P&G-Clairol,  Case No. 09 C 1723, Slip op. (N.D. Ill. March 18, 2011)(excluding expert witness who relied upon MSDS to support a claim of a severe allergic reaction to Clairol hair dye; the MSDS did not address human reactions or consumer exposure levels)

STATE DECISIONS REJECTING RELIANCE UPON MSDS

OHIO

Braglin v. Lempco Indus., Inc., 2007 Ohio 1964; 2007 Ohio App. LEXIS 1773 (2007) (affirming exclusion of expert witness who relied upon MSDS among other things, and opined that plaintiff’s pancreatic cancer was caused by chemicals in raw metal processing)

TEXAS

Brookshire Bros., Inc. v. Smith, 176 S.W.3d 37-38 & n.7, 2003 WL 21756411, *4 (Tex. App. – Houston [1st Dist.] 2003, no pet. ) (MSDS or warning label cannot, alone, provide the specific, detailed, reliable showing of causation to support an expert witness’s opinion)

Coastal Tankships U.S.A. Inc. v. Anderson, 87 S.W.3d 591, 611 (Tex. App.‑ Houston [1st Dist.] 2002, pet. denied) (statement of health “effects” in MSDS was not reliable evidence of causation)

See also Exxon Corp. v. Makofski, 116 S.W.3d 176, 187-88 (Tex. App. 2003) (“standards used by OSHA [and] the EPA” inadequate for causal determinations)

 

UNTOWARD DECISIONS

There is, of course, some factual complexity to these decisions; some MSDS obviously will list well-established causal relationship; others not.  The key point is that an MSDS is a tertiary source, compiled from primary sources at various levels in the hierarchy of evidence, as well as secondary reviews.  To make matters really murky, most MSDS must also report regulatory classifications and determinations, which often are not evidence-based.  Most of the “untoward” decisions, below, share typical fallacious elements:

  • treating MSDS as an admission by the manufacturer or seller;
  • confusing precautionary regulatory assessments with scientific determinations;
  • ignoring considerations of dose, exposure, route of exposure, animal species; and
  • confusing disease outcome discussed in MSDS with that claimed by plaintiff.

FEDERAL

Best v. Lowe’s Home Centers, Inc., 563 F.3d 171 (6th Cir. 2009), rev’g No. 3:04-CV-294, 2008 WL 2359986 (E.D. Tenn. June 5, 2008) (excluding expert witness who relied extensively upon MSDS)

Curtis v.M&S Petroleum, Inc. 174 F.3d 661, 669-70 (5th Cir. 1999) (reliance upon a particular MSDS was reasonable when the sheet was consistent with a body of reliable information about the hazards of benzene exposure)

Westberry v. Gislaved Gummi AB, 178 F.3d 257, 264-66 (4th Cir. 1999) (expert witness’s causation opinion of plaintiff’s sinus condition was reasonably based upon facts and data, including MSDS on talc)

McCullock v. H.B. Fuller Co., 61 F.3d 1038, 1043-44 (2d Cir.1995) (affirming denial of Rule 702 motion when expert witness’s causation opinion was based upon wide array of materials, including product’s MSDS)

Allen v. Martin Surfacing, 263 F.R.D. 47 (D. Mass. 2009) (denying challenge to expert witness who concluded that plaintiff’s exposure to neurotoxic levels of floor-surfacing chemical caused his ALS)

In re Stand ‘n Seal Prod. Liab. Litig., 1:07 MD1804-TWT, MDL 1804, Order Sur Longo (N.D. Ga. June 15, 2009)(denying motion to exclude expert witnesses who relied in part upon MSDS)

In re Welding Fume Prod. Liab. Litig., 2006 WL 4507859, *35 (N.D.Ohio 2006)( OMALLEY, J.); 2005 WL 1868046, *36 (N.D.Ohio) (denying challenge to expert witnesses who claimed that welding causes Parkinson’s disease on basis of general statements in MSDS that a component of welding fume (manganese) can be neurotoxic, without specification of dose or duration)

Westley v Ecolab, Inc., 2004 WL 1068805 (E.D.Pa. 2004) (denying motion against expert witness who relied upon MSDS)

Blandin Paper Co. v. J&J Industrial Sales, Inc., No. Civ.02-4858 ADM/RLE, 2004 WL 1946388 (D. Minn. Sept. 2, 2004) (denying motion to exclude plaintiff’s expert witness who relied in part upon MSDS)

Lentz v. Mason, Case No. 1:96-cv-02319-SMO, Slip op. (D.N.J. Jan. 11, 1999)(denying motion to exclude expert witness who relied up MSDS as well as independent testing)

STATE

Langness v. Fencil Urethane Systems, Inc., 2003 ND 132, 667 N.W.2d 596 (2003) (reversing jury verdict on grounds of error in excluding expert witness who relied in part upon MSDS for physical properties of material)

Johnson v. Arkema Inc. – The Fifth Circuit Proves to Be Sophisticated Consumer of Science

June 21st, 2012

Yesterday, in celebration of the first day of summer, the Fifth Circuit handed down a decision in a case that looks like a laundry list of expert witness fallacies.  Fortunately, the district judge and two of the three appellate judges kept their analytical faculties intact.  Johnson v. Arkema Inc., Slip op., 2012 WL ___ (5th Cir. June 20, 2012) (per curiam) (affirming exclusion of expert witnesses).

The plaintiff had worked in a glass bottling plant, where on two occasions in 2007, he was in close proximity to the defendant’s ventilation hood, designed to be used with a chemical, Certincoat, composed of monobutyltin trichloride (MBTC), an organometallic compound.  Plaintiff claimed that the ventilation was inadequate and that as a result he was exposed to MBTC as well as hydrochloric acid.

The plaintiff sustained some acute symptoms and ultimately was diagnosed with a “chemical pneumonia,” by his treating physician.  The plaintiff further claimed that his condition progressively worsened,  and that he was ultimately diagnosed with “pulmonary fibrosis,” a “severe restrictive lung disease.” The plaintiff filed reports from two expert witnesses – Richard Schlesinger, a toxicologist, and Charles Grodzin, a pulmonary physician – in support of his claim that his pulmonary fibrosis was caused by overexposure to MBTC and hydrochloric acid (HCl).

Plaintiff’s claim led to defendant’s Rule 702 challenge, which the trial court sustained, and the appellate court affirmed.

A basic problem faced by plaintiff is that there was virtually no evidence that MBTC or HCl causes pulmonary fibrosis. Undaunted, the plaintiff and his expert witnesses pushed on, but the lack of epidemiologic evidence associating MBTC or HCl with pulmonary fibrosis proved reliably harmful to plaintiff’s case.

General Acceptance

Plaintiff could point to no evidence that MBTC or HCl causes pulmonary fibrosis.  Slip op. at 7. Given the delay in manifestation of the fibrosis after the plaintiff’s rather limited, discrete exposures, the court recognized that epidemiologic evidence was important, if not essential, to plaintiff’s case. Without epidemiology, the plaintiff retreated to generalities – the chemicals cause lung irritation, lung injury, etc.  One concurring judge was taken in, but the majority of the panel saw through the dodge.

Anecdotal Evidence

Without epidemiologic evidence, the plaintiff invoked anecdotal evidence that other employees sustained similar lung injuries. The problem, however, for even this low-level evidence was that other employees experienced only transitory symptoms, which quickly resolved.  Id. at 4 -5, 27.

Post Hoc, Ergo Propter Hoc

Focusing only on himself as an anecdote with n =1, the plaintiff, and his expert witnesses, argued that temporal sequence of his exposure and his pulmonary fibrosis was itself evidence of causality.  Neither the trial court nor the appellate court found this much of an argument.  Id. at 16 n.13, 18.

Mechanism in Search of Data – Schlesinger’s irritant theory

Schlesinger argued that both MBTC and HCl are pulmonary irritants, which can cause inflammation, and pulmonary fibrosis results from inflammation. Id. at 8.  True, but not all irritants cause pulmonary fibrosis.  Chronicity and dose are important considerations.  Whether these chemicals, under exposure conditions experienced by plaintiff, were capable of causing pulmonary fibrosis, cried out for evidence.

The Material Safety Data Sheets (MSDS)

The plaintiff argued that the MSDS for HCl established that this chemical was “severely corrosive to the respiratory system.” Id. at 11-12.  The defendant’s own MSDS for MBTC stated that MBTC “causes respiratory tract irritation.” Id. at 16.  The courts saw these arguments as transparently absent evidence. None of the MSDS identified pulmonary fibrosis; nor did they specify (1) the underlying scientific support, or (2) the relevant duration and exposure needed to induce any particular adverse outcome.

Animal Studies

For both MBTC and HCl, plaintiff adverted to animal studies, but the courts found that the animal studies failed to support the plaintiff’s expert witnesses’ opinions and the plaintiff’s claims.  The studies were readily distinguishable in terms of dose, duration, and disease outcome.  In particular, none of the studies showed that the chemicals caused pulmonary fibrosis. Id. at 7, 12 (baboon study of HCl showed impairment but not fibrosis at 10,000ppm for one year, quite unlike plaintiff’s exposure), 16-17 (rat inhalation study of MBTC, six hrs/day, five days/wk, up to 30 mg/m3, with toxicity but no mention of lung fibrosis).

Regulatory Limits

Plaintiff argued that HCl levels were multiples of the OSHA limits, but the courts would not credit regulatory exposure limits are evidence of harmfulness because of the precautionary nature of many regulations.  Id. at 14.  Furthermore, the disease outcomes of regulatory concern did not appear to be pulmonary fibrosis for the chemicals involved.

Res Ipsa Loquitur

The plaintiff argued that causation was a matter of common sense and general experience.  Even if his expert witnesses did not have valid, reliable evidence, the jury could make the causal determination without scientific evidence. Id. at  26.  Rejected.

Chemical Analogies

The defendant’s expert witness acknowledged that tin oxide can cause pulmonary fibrosis.  Id. at 28.  This admission, however, came without any qualification about what exposure or duration data might be needed to support a conclusion about specific causation in the plaintiff.  Id.  Furthermore, tin pneumoconiosis, or stannosis, is known as a benign lung disease, unassociated with impairment or disability.  Like simple silicosis, stannosis is a picture change on chest radiograph, without diminution of performance on pulmonary function tests.  Agency for Toxic Substances and Disease Registry, A Toxicological Profile for Tin and Tin Compounds at 30 (2005).

Differential Diagnosis

Plaintiff’s pulmonary expert witness, Dr. Grodzin, tried to bootstrap specific causation by assuming general and putting it in the “differentials” for him to embrace.  Id. at 19.  A fallacious form of reasoning, but the courts here were on top of it.

* * * * *

The panel did reverse the trial court’s grant of summary judgment.  The gate closed a little too fast to permit scrutiny of plaintiff’s claim of acute injuries and symptoms, which were less dependent upon epidemiologic evidence.

 

Meta-Meta-Analysis – Celebrex Litigation – The Claims – Part One

June 21st, 2012

In the Celebrex/Bextra litigation, both sides acknowledged the general acceptance and validity of meta-analysis, for both observational studies and clinical trials, but attacked the other side’s witnesses’ meta-analyses on grounds specific to how they were conducted.  See, e.g., Pfizer Defendants’ Motion to Exclude Certain Plaintiffs’ Experts’ Causation Opinion Regarding Celebrex – Memorandum of Points and Authorities in Support Thereof at 14, 16 (describing meta-analysis as “appropriate” and a “useful way to evaluate the presence and consistency of an effect,” and “a valid technique for analyzing the results of both randomized clinical trials and observational studies”)(dated July 20, 2007), submitted in MDL 1699, In re Bextra and Celebrex Marketing Sales Practices & Prod. Liab. Litig., Case No. 05-CV-01699 CRB (N.D. Calif.) [hereafter MDL 1699]; Plaintiffs’ Memorandum of Law in Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 2 (July 23, 2009) (“While use of a properly conducted meta-analysis is appropriate, there are underlying scientific principles and techniques to be used in meta-analysis that are widely accepted among biostatisticians and epidemiologists. Wei’s meta-analysis – which he acknowledges is based in part on an admittedly novel approach that is not generally recognized by the scientific community – fails to follow certain of these key principles.”), submitted in In re Pfizer, Inc. Securities Litig., Nos. 04 Civ. 9866(LTS)(JLC), 05 md 1688(LTS) (S.D.N.Y.)[hereafter Securities Litig.]

The plaintiffs and defendants expended a great deal of energy in attacking the other side’s meta-analyses as conducted.  With all the briefing in the federal MDL, the New York state cases, and the securities fraud class action, hundreds of pages were written on the suspected flaws in meta-analyses.  The courts, in both the products liability MDL cases and in the securities case, denied the challenges in a few sentences.  Indeed, it is difficult if not impossible to discern what the challenges were from reading the courts’ decisions. In re Pfizer Inc. Securities Litig., 2010 WL 1047618 (S.D.N.Y. 2010); In re Bextra and Celebrex, 2008 N.Y. Misc. LEXIS 720; 239 N.Y.L.J. 27(2008); In re Bextra and Celebrex Marketing Sales Practices and Product Liability Litig., MDL No. 1699, 524 F.Supp. 2d 1166 (N.D. Calif. 2007)

Although the issues shifted some over the course of these litigations, certain important themes recurred.  The plaintiffs focused their attack upon the meta-analyses conducted by defense expert witness, Lee-Jen Wei, a professor of biostatistics at the Harvard School of Public Health.

The plaintiffs maintained that Professor Wei’s meta-analyses should be excluded under Rule 702, or the New York case law, because of

  • inclusion of short-term clinical trials
  • failure to weight risk ratios by person years
  • inclusion of zero-event trials with use of imputation methods
  • use of risk difference instead of risk ratios
  • use of exact confidence intervals instead of estimated intervals

See generally Plaintiffs’ Memorandum of Law in Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei (July 23, 2009), in Securities Litig.

The plaintiffs advanced meta-analyses conducted by Professor David Madigan, Professor and Chair in the Department of Statistics, Columbia University.  The essence of the defendants’ challenges revolved around claims of flawed outcome and endpoint ascertainment and definitions:

  • invalid clinical endpoints
  • flawed data collection procedures
  • ad hoc changes in procedure and methods
  • novel methodologies “never used in the history of clinical research”
  • lack of documentation for classifying events
  • absence of expert clinical judgment in classifying event for inclusion in meta-analysis
  • creation of composite endpoints that included events unrelated to plaintiffs’ theory of thrombotic mechanism
  • lack of blinding to medication use when categorizing events
  • failure to adjust for multiple comparisons in meta-analyses

See generally Pfizer Defendants’ Motion to Exclude Certain Plaintiffs’ Experts’ Causation Opinion Regarding Celebrex – Memorandum of Points and Authorities in Support Thereof (dated July 20, 2007), in MDL 1699; Pfizer defendants’ [Proposed] Findings of Fact and Conclusions of Law with Respect to Motion to Exclude Certain Plaintiffs’ Experts’ Opinions Regarding Celebrex and Bextra, and Plaintiffs’ Motion to Exclude Defendants’ Expert Dr. Lee-Jen Wei, Document 175, submitted in Securities Litig. (Dec. 4, 2009).

Why did the three judges involved (Judge Breyer in the federal MDL; Justice Kornreich in the New York state cases; and Judge Swain in the federal securities putative class action) give such cursory attention to these Rule 702/Frye challenges?  The complexity of the issues, the lack of clarity in the lawyers’ briefings, and the stridency of both sides perhaps contributed to shorten judicial attention span.  Some of the claims were simply untenable, and may have obliterated more telling critiques.

ZERO-EVENT TRIALS

Many of the Celebrex parties’ claims can be traced to a broader issue of what to include or exclude in a meta-analysis.  Consider for instance the plaintiffs’ challenge to Wei’s meta-analysis.  The plaintiffs faulted Wei for including short-term clinical trials in his meta-analysis, while sponsoring their own expert witness testimony that Celebrex could induce heart attack or stroke after first ingestion of the medication.  Having made the claim, the plaintiffs were hard pressed to exclude short-term trials, other than to argue that such trials frequently had zero adverse events in either the medication or placebo arms.  Many meta-analytic methods, which treat each included study as a 2 x 2 contingency table, and calculate an odds ratio for each table, cannot accommodate zero event data.

Whether or not hard pressed, the plaintiffs made the claim. The plaintiffs’ analogized to the lack of reliability of underpowered clinical trials to provide evidence of safety.  See Plaintiffs’ Reply Memorandum of Law in Further Support of Their Motion to Exclude Expert Testimony by Defendants’ Expert Dr. Lee-Jen Wei at 6 (May 5, 2010), in Securities Litig. (citing In re Neurontin Mktg., Sales Practices, and Prod. Liab. Litig., 612 F. Supp. 2d 116, 141 (D. Mass. 2009) (noting that many of Pfizer’s studies were “underpowered” to detect the alleged connection between Neurontin and suicide).  The power argument, however, does not make sense in the context of a meta-analysis, which is aggregating data across studies to overcome the alleged lack of power in a single study.

Not surprisingly, clinical trials of a non-cardiac medication will often report no event of the outcome of interest, such as heart attack.  These trials are referred to as a “zero event”, which can happen in one or both arms of a given trial.  Some searchers exclude these studies from a meta-analysis because of the impossibility of calculating an odds ratio without using imputation in the zero cells of the 2 x 2 tables. Although there are methods to address zero-event trials, some researchers believe that the existence of several zero-event trials essentially means that the sparse data from rare outcomes deprives statistical tests of their usual meaning.  Traditional statistical standards of significance (p < 0.05) are described as “tenuous,” and too high, in this situation. A.V. Hernandez, E. Walker, J. P. Ioannidis, M.W. Kattan, “Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone,” 156 Am. Heart J. 23, 28 (2008).

The exclusion of zero-event trials from meta-analyses of rare outcomes can yield biased results. See generally M.J. Bradburn, J.J Deeks, J.A. Berlin, and A. Russell Localio,” Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events,” 26 Statistics in Med. 53 (2007); M.J. Sweeting, A.J. Sutton, and P.C. Lambert, “What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data,” 23 Statistics in Med. 1351 (2004)(erratum at 25 Statistics in Med. 2700 (2006) (“Many routinely used summary methods provide widely ranging estimates when applied to sparse data with high imbalance between the size of the studies’ arms. A sensitivity analysis using several methods and continuity correction factors is advocated for routine practice.”).

Others researchers include zero-event trials as providing helpful information about the absence of risk. Zero-event trials:

“provide relevant data by showing that event rates for both the intervention and control groups are low and relatively equal. Excluding such trial data potentially increases the risk of inflating the magnitude of the pooled treatment effect.”

J.O. Friedrich, N.K. Adhikari, J. Beyene, “Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data,” 5 BMC Med. Res. Methodol. 2 (2007)[cited as Friedrich].  Zero event trials can be included in meta-analyses by using something called a standard “continuity correction,” which involves imputing events, or fractional events, in all cells of the 2 x 2 table. One approach, the zero is replaced with 0.5 and all other numbers are increased by 0.5. Friedrich at 7.

After examining the bias in several meta-analyses from excluding zero-event trials, Friedrich and colleagues recommended:

“We believe these trials [with zero events] should also be included if RR [relative risks] or OR [odds ratios] are the effect measures to provide a more conservative estimate of effect size(even if this change in effect size is very small for RR and OR), and to provide analytic consistency and include the same number of trials in the meta-analysis, regardless of the summary effect measure used. Inclusion of zero total event trials would enable the inclusion of all available randomized controlled data in a meta-analysis, thereby providing the most generalizable estimate of treatment effect.”

Friedrich at 5-6.

Wei addressed the problem of zero-event trials by using common imputation methods, not so different from what plaintiffs’ expert witness Dr. Ix used in the gadolinium litigation. See Meta-Meta-Analysis — The Gadolinium MDL — More Than Ix’se Dixit.  Given that plaintiffs advanced a mechanistic theory, which would explain cardiovascular thrombotic events almost immediately upon first ingestion of Celebrex, Professor Wei’s attempt to save the data inherent in zero-event trials by “continuity correction” or imputation methods seems reasonable and well within meta-analytic procedures.

 

RISK DIFFERENCE

Professor Wei did not limit himself to a single method or approach.  In addition to using imputation methods, Wei used risk difference, rather than risk ratios, as the parameter of interest.  The risk difference is simply the difference between two risks: the risk or probability of an event in one group less the risk or probability of that event in another group.  Contrary to the plaintiffs’ claims, there is nothing novel or subversive about conducting a meta-analysis with the risk difference as the parameter of interest, rather than a risk ratio.  In the context of randomized clinical trials, the risk difference is expected as a measure of absolute effect.  See generally, Michael Borenstein, L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein, Introduction to Meta-Analysis (2009); Julian PT Higgins and Sally Green, eds., Cochrane Handbook for Systematic Reviews of Interventions (2008)

Like risk ratios, the risk difference yield a calculated confidence interval at any desired coefficient of confidence.  Confidence intervals for dichotomous events are often based upon approximate methods that build upon the normal approximation to the binomial distribution.  These approximate methods require assumptions of sample size that may not be met in cases involving sparse data.  With modern computers, calculating exact confidence intervals is not particularly difficult, and Professor Wei has published a methods paper in which he explains the desirability of using the risk difference with exact intervals in addressing meta-analyses of sparse data, such as was involved in the Celebrex litigation.  See L. Tian, T. Cai, M.A. Pfeffer, N. Piankov, P.Y. Cremieux, and L.J. Wei, “Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction,” 10 Biostatistics 275 (2009).

Plaintiffs attacked Wei’s approach as “novel” and not generally accepted.  Judge Swain appropriately dismissed this attack:

“Dr. Wei’s methodology, the validity of which Plaintiffs contest and the novelty of which Plaintiffs seek to highlight, appears to have survived the rigors of peer review at least once, and is subject to critique by virtue of its transparency. Dr. Wei’s report, supplemented by his declaration, is sufficient to meet Defendants’ burden of demonstrating that his testimony is the product of reliable principles and methods. He has explained his methods, which can be tested. Plaintiffs’ critiques of Dr. Wei’s choices regarding which trials to include in his own meta-analysis, the origins of the data he used, the date at which he undertook his meta-analysis, and at whose behest he performed his analysis all go to the weight of Dr. Wei’s testimony.”

In re Pfizer Inc. Securities Litig., 2010 WL 1047618, *7 (S.D.N.Y. 2010).  The approach taken by Wei is novel only in the sense that researchers have not previously tried to push the methodological envelope of meta-analysis to deploy the technique for rare outcomes and sparse data, with many zero-event trials.  The risk difference approach is well suited to the situation, and the use of exact confidence intervals is hardly novel or dubious.

Expert Witness Guru

June 20th, 2012

In my casting about on the internet, I came across an interesting site dedicated to expert witness issues:  The Expert Witness Guru (EWG).

As you might expect, the Expert Witness Guru is an India-based “expert witness consulting and publishing firm, with a distinct focus on helping experts build a robust practice and providing attorneys with the right tools to locate and engage the right experts.”  The website is a blend of marketing and scholarship, which is designed to be helpful to both expert witnesses and to lawyers who depend so much upon their experts in litigation.  The EWG offers a variety of litigation support services, including preparation of expert witness profiles and deposition summaries.

The website features a blog, the Expert Witness Marketing and News Blog, which is designed with the mixed readership of both expert witnesses and lawyers in mind.  The EWG blog publishes the work of the folks at EWG, as well as invited guest posts.  Expert Witness Guru also publishes an electronic monthly magazine, Expert Witness Chronicle, with coverage of the law, practice, and marketing of expert witness testimony.  To date, two issues have been released, which are available at the EWG website.

The editorial staff of Expert Witness Chronicle includes Ashish Arun (Editor), Shweta Nawani (Co-Editor), and contributors John F. Fielder, Myles Levin, and Gil Zamora.

The second issue of the Expert Witness Chronicle announced the formation of a capable editorial board, of well-respected scholars and practictioners:

Joseph P. Sanders, the A. A. White Professor of Law at University of Houston Law Center

Edward K. Cheng, Professor of Law at Vanderbilt Law School, and

John F. Fielder, clinical and forensic psychologist, and CEO, Daubert Institute of Forensic Psychology

The first two issues feature interesting coverage of the whole range of expert witness issues, from practice issues involving retention to the wide spectrum of types of expert witness testimony (forensic, economic, engineering, scientific, etc.).  The website, blog, magazine, and the outsourced services are all worth a closer look.

 

 

NIOSH Report Sets Up Run on September 11th Victim Compensation Fund by Non-Victims

June 16th, 2012

Congress created September 11th Victim Compensation Fund, 49 USC § 40101, to compensate victims of the terrorist attack.  Being a victim implies that the harm to be compensated was caused by the attack and its consequences.  Understandably, many of the harms were acute injuries, but what about cancer?  The latency period for most cancers are greater than 10 years, and the latency alone would suggest that persons who developed cancer within 10 years were not “victims,” but rather expected incidences of prevalent, chronic disease, or the result of much earlier exposures in the patients’ lifetimes.

Less than a year ago, the New York Times reported on a NIOSH report, which documented that there was little evidence upon which to rely, and what was available did not support conclusions of causality.  See Anemona Hartocollis, “Scant Evidence to Link 9/11 to Cancer, U.S. Report Says,” N.Y. Times (July 26, 2011).  The report appropriately noted that “[d]rawing causal inferences about exposures resulting from the Sept. 11, 2001, terrorist attacks and the observation of cancer cases in responders and survivors is especially challenging since cancer is not a rare disease.”

A few months later, the Times reported on an epidemiologic study of firefighters who were present at the World Trade Center in 2001.  Sydney Ember, “Study Suggests Higher Cancer Risk for 9/11 Firefighters,” N.Y. Times (Sept. 1, 2011).  According to the Times, the study:

“says firefighters who toiled in the wreckage of the World Trade Center in 2001 were 19 percent more likely to develop cancer than those who were not there, the strongest evidence to date of a possible link between work at ground zero and cancer. The study, published Thursday in the British medical journal The Lancet, included almost 10,000 New York City firefighters, most of whom were exposed to the caustic dust and smoke created by the fall of the twin towers. The findings indicate an “increased likelihood for the development of any type of cancer,” said Dr. David J. Prezant, the chief medical officer for the New York Fire Department, who led the study. But he said the results were far from conclusive. ‘This is not an epidemic’, he said.”

Well this is just bad reporting; the study said nothing of the sort.  The study reported a non-statistically significant standardized incidence ratio for all cancer, of either 1.10 (95% CI 0·98–1·25), with a comparison group of the generalized U.S. male population, or 1·19 (95% CI 0·96–1·47), with unexposed firefighters as a comparison group, and corrected for possible surveillance bias.  Here are the authors’ (including Dr. Prezant’s) published interpretation of the data:

“We reported a modest excess of cancer cases in the WTC-exposed cohort. We remain cautious in our interpretation of this finding because the time since 9/11 is short for cancer outcomes, and the reported excess of cancers is not limited to specific organ types. As in any observational study, we cannot rule out the possibility that effects in the exposed group might be due to unidentified confounders. Continued follow-up will be important and should include cancer screening and prevention strategies.

Rachel Zeig-Owens, Mayris Webber, Charles Hall, Theresa Schwartz, Nadia Jaber, Jessica Weakle , Thomas Rohan, Hillel Cohen, Olga Derman, Thomas Aldrich, Kerry Kelly, David  Prezant, “Early assessment of cancer outcomes in New York City firefighters after the 9/11 attacks: an observational cohort study,” 378 Lancet 898, 898 (2011) [hereafter Zeig-Owens].

The Zeig-Owens study was a cohort of New York firefighters who had worked at the WTC in the immediate aftermath of the attack.  The data neither ruled out chance nor bias and confounding as a basis for the reported risk ratios. The potentially toxic exposures at the WTC were only some of the exposures these men experienced over their careers.  Comparisons with the general population are thus not terribly revealing, but the study also compared the firefighters with other firefighters who did not work at the WTC.

For firefighters, lung cancer is typically a concern, but the Zeig-Owens study reported that the WTC firefighters had a lower than expected incidence of lung cancer:

lung cancer 0.53 (95% CI 0.18 – 1.54)

Some cancers had an elevated SIR, which is also expected given that the study looked at dozens of different outcomes.  Esophageal cancer was typical of the few that cancers that fell above 1.0; the SIR was 1.32, but the 95% confidence interval was huge, running from 0.12 to 14.53.  Understandably the authors of the WTC study did not assert any causal conclusions.

The lack of causal conclusions and evidence did not ultimately stand in the way of politics.  Last week, John Howard, the director of the National Institute of Occupational Safety and Health (NIOSH) issued his ruling that some 50 different types of cancer be added to the illnesses and injuries covered by the 9/11 Compensation Fund.  Anemona Hartocollis, “Sept. 11 Health Fund Given Clearance to Cover Cancer,” N.Y. Times (June 8, 2012).

Not only is Howard’s report not based upon appropriate scientific conclusions of causality, it is a ghastly insult to those men and women who were truly victims of the attack.  On virtually no evidence at all, Howard’s decision dilutes the fund for those truly injured.  The extent of the dilution is disturbing; the decision will not only allow the victims and the heroic rescuers to apply for compensation for cancers, but it will allow residents and passerbys to do so, as well.

The Times quoted Dr. Howard as stating that the Zeig-Owens study provided “a strong foundation for a conclusion that some cancers had been caused by exposure to the WTC debris.”  This is rubbish.  Coming from the director of a supposedly scientific agency, the statement is shocking.  As noted above, the lung cancer incidence ratio for WTC firefighters was lower than expected, compared to either non-WTC firefighters or the general male population.  The presence of “known or potential carcinogens” in the debris hardly justifies compensation unless the exposures were at sufficient intensity and duration, with appropriate latencies, to have caused the claimed cancers.  Howard’s report is shamelessly bereft of evidence to support bilking the compensation fund, and diverting compensation from true victims of the jihadist attack.

Although the Times ignored the primary data, it did acknowledge that Howard’s report, and the recommendation upon which he relied, seemed to be based upon “societal concerns that the cancer patients not be left out of the fund.”  This is interest-group politics substituting for science.

The Times quoted Dr. Alfred I. Neugut, an oncologist and professor of epidemiology at the Mailman School of Public Health at Columbia University, as stating that the decision was “primarily motivated by concern for a sympathetic population,”  and that “[t]he scientific evidence currently is certainly weak; whether future evidence bears out the wisdom of this decision will have to be seen.”

But “weak” is understatement.  The Zeig-Owens study looked at dozens of organ cancers and subtypes; it was a huge exercise in data mining, which can best be described as hypothesis generating.  Howard, however, decided to reject any semblence of evidence-based medicine:

“Requiring evidence of positive associations from studies of 9/11-exposed populations exclusively does not serve the best interests.”

So apparently positive associations are no longer required; compensation can be based upon negative associations, as was the case with WTC firefighting and lung cancer.

The Times cheered Howard’s decision in an editorial that followed quickly on the heels of the NIOSH report. “Ground Zero Cancers” (June 14, 2012).  The Times acknowledged that “[s]ome experts still believe the evidence linking the Sept. 11 attacks to cancers is weak. But we have a moral obligation to ensure that those harmed by exposure at ground zero get the medical and financial help they need.”

But “weak” is a gross overstatement, and whence comes a moral obligation to help those not harmed by exposure at ground zero?  Where is the morality of diluting the compensation fund for those who were truly victims.  Howard’s report represents not only an abdication of the evidence-based world view, but profound disrespect for those were killed and maimed in this brutal attack.

Predictably, plaintiffs’ counsel have already urged mesothelioma patients to consider the fund.  SeeLawyer Urges NYC Mesothelioma Sufferers to Explore Options after Decision Expanding 9/11 Fund,” New York, NY (PRWEB) (June 16, 2012) (“New York mesothelioma lawyer Joseph W. Belluck today said that 9/11 workers with mesothelioma should step forward to explore their eligibility for compensation in light of a federal ruling that greatly expands the scope of a $4.3 billion fund established to compensate and treat people exposed to toxic smoke, dust and fumes following the Sept. 11, 2001, terrorist attacks.”) No mesothelioma cases were reported as incident among the WTC exposed firefighters.

An internet search on ” cancer 9/11 compensation fund” turned up dozens of lawyer advertisements and websites urging cancer claims against the Fund.

The WABAC on the Wayback Machine – Proving Up Internet History

June 16th, 2012

Every TV-literate American of my generation knows that Mr. Peabody and his boy, Sherman, invented a time machine, the “WABAC machine,” which allowed them to travel back in time to explore, and to alter, historical events. The Rocky and Bullwinkle Show. My children know that the universe began with the creation of the internet, and that all you need to visit the past is the Wayback Machine, at http://archive.org/index.php

The content of the internet is not static; webpages come and go.  The Wayback Machine periodically archives snapshots of webpages, and makes them available for review.  The Wayback Machine has great utility for investigative journalists, historians, and, of course, lawyers.  See Healthcare Advocates, Inc. v. Harding, Earley, Follmer & Frailey, 497 F. Supp. 2d 627 (E.D. Pa. 2007) (describing the Internet Archive as “a nonprofit organization that has created an online library of digital media in an effort to preserve digital content for future reference. Its digital database is equivalent to a paper library, but is filled with digital media like websites instead of books. The library includes a collection of chronological records of various websites which Internet Archive makes available at no cost to the public via the Wayback Machine. The library’s records include more than 85 billion screenshots of web pages which are stored on a computer database in California. Internet Archive’s database provides users with the ability to study websites that may have been changed or no longer exist.”).

A few years ago, when I was practicing in Philadelphia, an out-of-town firm filed over 100 silicosis cases in the Court of Common Pleas.  The cases were generated by screenings funded and organized by the plaintiffs’ firm.  The plaintiffs’ and defense counsel tussled over the propriety of the screenings, and the plaintiffs’ firm insisted that it did not historically conduct radiographic screenings for pneumoconiosis cases.  A simple search for the plaintiffs’ firm’s website, on The Wayback Machine, told a different story.   See Schachtman, “State Regulators Impose Sanction for Unlawful Silicosis Screenings,” 17(13) Wash. Leg. Fdtn. Leg. Op. Ltr. (May 25, 2007).

Proving the past content of the plaintiffs’ firm’s website never became an issue in the Philadelphia silicosis issue, but the Wayback Machine has figured in other litigation where authentication was required.  United States v. Bansal, 663 F.3d 634 (3d Cir. 2011);  Keystone Retaining Wall Sys., Inc. v. Basalite Concrete Prods., LLC, 2011 U.S. Dist. LEXIS 145545, n.9 (D. Minn. Dec. 19, 2011) (noting that federal courts have regularly accepted evidence from the Internet Archive); St. Luke’s Cataract & Laser Inst., P.A. v. Sanderson, No. 8:06-CV-223, 2006 U.S. Dist. LEXIS 28873, at *6, 2006 WL 1320242, at *2 (M.D. Fla. May 12, 2006) (noting that a screen capture from the Internet Archive could be printed out and authenticated with an affidavit from a “representative of Internet Archive with personal knowledge of its contents, verifying that the printouts Plaintiff seeks to admit are true and accurate copies of Internet Archive’s records”).

There is also a significant secondary literature describing authentication procedures.  See WAYBACK MACHINE MEMO: Report of the Discovery Practices and Procedures Subcommittee of the Enforcement Committee (Nov. 2009) (collecting cases and urging authentication by judicial notice or stipulation); Wayback Machine Frequently Asked Questions (describing model affidavit for authentication, and alternative procedures in lieu of affidavit).

See also Kenneth N. Rashbaum, Matthew F. Knouff, and Dominique Murray, “Admissibility of Non-U.S. Electronic Evidence,” 18 Richmond J. L. & Tech. 9 (2012);  Rebecca Levy-Sachs & Jason Curtin, “Clearing Hurdles to Admission,” For The Defense 24 (Jan. 2011); James Gibson & Ketan Bhirud, “Admitting Web Pages Into Evidence,” Nevada Lawyer 15 (Oct. 2010); Deborah R. Eltgroth, “Best Evidence and the Wayback Machine: Toward a Workable Authentication Standard for Archived Internet Evidence,” 78 Fordham L. Rev. 181 (2009); Beryl A. Howell, “Proving Web History: How to Use the Internet Archive,” J. Internet Law 3 (Feb. 2006); Gregory P. Joseph, “Internet Archive (Wayback Machine) Printouts Received in Evidence on Preliminary Injunction Motion Evidently without Further Authentication — Courts Warming to Reliability“; Federal Evidence Review, “Authenticating Internet Screenshot Evidence Under FRE 901” (Dec. 19, 2011) (describing Bansal case and its review of authentication methods for the Wayback Machine archive of website pages).